… mutation and the risk of recurrence. The strongest argument against using BRAF mutation as
… At present it seems that BRAF mutation is one of the factors influencing the prognosis and it …

… the BRAF V600E mutation was associated with an increased recurrence rate of papillary
thyroid carcinoma (… to assess the impact of the BRAF V600E mutation on PTC recurrences. We …

… To investigate the mutant status of BRAF gene and analyze its relationship to epidemiological
risk factors and clinical outcomes among patients with papillary thyroid cancer (PTC) in the …

… T1799A BRAF mutation in patients with papillary thyroid cancer. Cancer 2008;113:247-255. …
between STAT1 activity and BRAF mutations in papillary thyroid carcinomas. J Surg Oncol …

… Studies found that BRAF V600E status would be … of BRAF V600E , the associations of
BRAF V600E with the clinicopathological features of PTC patients and the impact of this mutation …

… BRAF mutations are closely associated with … in papillary thyroid cancer. Accordingly,
aggressive treatment should be considered for papillary thyroid cancer patients with BRAF mutation. …

… : The BRAF V600E mutation is closely related to serum Tg elevation after treatment with
iodine-131 in papillary thyroid cancer. These findings suggest that this BRAF mutation may be a …

… of the BRAF mutation in our cohort of papillary thyroid cancer patients was 56%. BRAF
mutation-positive tumours were associated with a more locally advanced disease, and these …

… The BRAF V600E mutation is a recognised molecular marker in papillary thyroid cancer (PTC),
reported incidence from 30 to 80 %. BRAF V600E aberrantly activates the MAPK pathway…

… We aim to investigate the risk factors that may predict the BRAF V600E mutation potential of
… 9,908 papillary thyroid carcinoma patients with average 74.6% BRAF V600E mutations were …